XT
ACXP icon

XTX Topco’s Acurx Pharmaceuticals ACXP Stock Holding History

XTX Topco’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,884
Closed -$19.2K – 2488
2025
Q2 		$19.2K Buy
+1,884
New +$15.2K ﹤0.01% 2169
2024
Q2 		– Sell
-652
Closed -$31.9K – 1800
2024
Q1 		$31.9K Buy
+652
New +$42.4K ﹤0.01% 1545

Other funds holding ACXP

PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.33B AUM 24% 1-Year Est. Return
CPG
Cornerstone Planning Group Fairfield, New Jersey $749M AUM 17.97% 1-Year Est. Return
GWSG
GPS Wealth Strategies Group Centennial, Colorado $117M AUM 24.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

XTX Topco's ACXP Position: Q3 2025 in Review

XTX Topco sold out of Acurx Pharmaceuticals (ACXP) in Q3 2025, closing a stake of 1,884 shares — an estimated $19.2K sold.

XTX Topco first reported a position in ACXP in Q1 2024 and held it in 2 quarters. The position peaked at $31.9K in Q1 2024. 16 funds tracked by Wall St. Rank hold ACXP as of Q3 2025.

  • XTX Topco reported no remaining Acurx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • XTX Topco sold 1,884 Acurx Pharmaceuticals shares in Q3 2025, an estimated $19.2K.
  • XTX Topco first reported a position in Acurx Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • XTX Topco's Acurx Pharmaceuticals position peaked at $31.9K in Q1 2024.
  • 16 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q3 2025.

Based on XTX Topco's 13F filing for Q3 2025, filed 14 Nov 2025.